Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

IF 4.6 Q1 ONCOLOGY 癌症耐药(英文) Pub Date : 2023-01-01 DOI:10.20517/cdr.2023.13
Won-Hee Yoon, Anna DeFazio, Lawrence Kasherman
{"title":"Immune checkpoint inhibitors in ovarian cancer: where do we go from here?","authors":"Won-Hee Yoon,&nbsp;Anna DeFazio,&nbsp;Lawrence Kasherman","doi":"10.20517/cdr.2023.13","DOIUrl":null,"url":null,"abstract":"<p><p>Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and despite advancements in therapeutics, most women unfortunately still succumb to their disease. Immunotherapies, in particular immune checkpoint inhibitors (ICI), have been therapeutically transformative in many tumour types, including gynaecological malignancies such as cervical and endometrial cancer. Unfortunately, these therapeutic successes have not been mirrored in ovarian cancer clinical studies. This review provides an overview of the ovarian tumour microenvironment (TME), particularly factors associated with survival, and explores current research into immunotherapeutic strategies in EOC, with an exploratory focus on novel therapeutics in navigating drug resistance.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344730/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症耐药(英文)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/cdr.2023.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and despite advancements in therapeutics, most women unfortunately still succumb to their disease. Immunotherapies, in particular immune checkpoint inhibitors (ICI), have been therapeutically transformative in many tumour types, including gynaecological malignancies such as cervical and endometrial cancer. Unfortunately, these therapeutic successes have not been mirrored in ovarian cancer clinical studies. This review provides an overview of the ovarian tumour microenvironment (TME), particularly factors associated with survival, and explores current research into immunotherapeutic strategies in EOC, with an exploratory focus on novel therapeutics in navigating drug resistance.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
免疫检查点抑制剂在卵巢癌中的应用:我们将何去何从?
上皮性卵巢癌(EOC)是最致命的妇科恶性肿瘤,尽管治疗方法有所进步,但大多数妇女仍然不幸死于这种疾病。免疫疗法,特别是免疫检查点抑制剂(ICI),已经在许多肿瘤类型,包括妇科恶性肿瘤,如宫颈癌和子宫内膜癌的治疗变革。不幸的是,这些治疗的成功并没有反映在卵巢癌的临床研究中。这篇综述综述了卵巢肿瘤微环境(TME),特别是与生存相关的因素,并探讨了EOC免疫治疗策略的当前研究,重点是探索性的新治疗方法,以导航耐药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.60
自引率
0.00%
发文量
0
期刊最新文献
Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers. Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy. Intercellular transfer of multidrug resistance mediated by extracellular vesicles. Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro. Non-coding RNA and drug resistance in head and neck cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1